Zevra Therapeutics down as FDA extends review for genetic disorder treatment

Zevra Therapeutics

04/03/2024 14:55

(Updates)
    ** Shares of rare disease focused Zevra Therapeutics
 ZVRA.O  down 11.2% at $6.3 in early trading 
    ** Company says U.S. FDA extended its decision on marketing
application of ZVRA's experimental treatment, arimoclomol, for
an ultra-rare genetic disorder
    ** Company is seeking approval for the candidate to treat
Niemann-Pick disease type C, which causes abnormal accumulation
of cholesterol and other fatty substances in the body
    ** Zevra receives notification from FDA that it required
more time to review the additional analyses provided by the
company upon the agency's request following a review
    ** FDA has set a new target action date of Sept. 21, 2024 vs
June 21 earlier
    ** ZVRA stock down more than 3.8% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))